UY35197A - Formulaciones topicas que contienen pidotimod - Google Patents

Formulaciones topicas que contienen pidotimod

Info

Publication number
UY35197A
UY35197A UY0001035197A UY35197A UY35197A UY 35197 A UY35197 A UY 35197A UY 0001035197 A UY0001035197 A UY 0001035197A UY 35197 A UY35197 A UY 35197A UY 35197 A UY35197 A UY 35197A
Authority
UY
Uruguay
Prior art keywords
topical formulations
formulations containing
pidotimod
containing pidotimod
psoriasis
Prior art date
Application number
UY0001035197A
Other languages
English (en)
Inventor
Caserini Maurizio
Mailland Federico
Original Assignee
Polichem Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polichem Sa filed Critical Polichem Sa
Publication of UY35197A publication Critical patent/UY35197A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención está dirigida a formulaciones tópicas que contienen pidotimod, o una sal fisiológicamente aceptable del mismo, junto con al menos un excipiente farmacéuticamente aceptable; tales formulaciones tópicas, que son preferentemente semi-sólidas o líquidas, están principalmente destinadas al tratamiento de psoriasis y/o dermatitis atópica.
UY0001035197A 2012-12-19 2013-12-17 Formulaciones topicas que contienen pidotimod UY35197A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2012/076086 WO2014094839A1 (en) 2012-12-19 2012-12-19 Use of pidotimod to treat atopic dermatitis

Publications (1)

Publication Number Publication Date
UY35197A true UY35197A (es) 2014-06-30

Family

ID=47520053

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035197A UY35197A (es) 2012-12-19 2013-12-17 Formulaciones topicas que contienen pidotimod

Country Status (32)

Country Link
US (1) US20150352081A1 (es)
EP (1) EP2934520B1 (es)
JP (1) JP6058156B2 (es)
KR (1) KR20150095772A (es)
CN (1) CN104797254B (es)
AU (1) AU2012396941A1 (es)
BR (1) BR112015011394A2 (es)
CA (1) CA2889388A1 (es)
CY (1) CY1118633T1 (es)
DK (1) DK2934520T3 (es)
EA (1) EA201591184A1 (es)
EC (1) ECSP15025570A (es)
ES (1) ES2615748T3 (es)
HK (1) HK1210938A1 (es)
HR (1) HRP20161667T1 (es)
HU (1) HUE030408T2 (es)
IL (1) IL239292A0 (es)
LT (1) LT2934520T (es)
MA (1) MA38156B1 (es)
ME (1) ME02559B (es)
MX (1) MX2015008129A (es)
PH (1) PH12015501211A1 (es)
PL (1) PL2934520T3 (es)
PT (1) PT2934520T (es)
RS (1) RS55424B1 (es)
SG (1) SG11201503281QA (es)
SI (1) SI2934520T1 (es)
SM (1) SMT201700071B (es)
TN (1) TN2015000159A1 (es)
UY (1) UY35197A (es)
WO (1) WO2014094839A1 (es)
ZA (1) ZA201502983B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015036009A1 (en) * 2013-09-10 2015-03-19 Polichem S.A. Pidotimod for use in the treatment of inflammation-associated diseases
EP3754806A1 (en) 2019-06-19 2020-12-23 UTC Fire & Security EMEA BVBA Power supply device

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1231723B (it) * 1989-08-11 1991-12-21 Poli Ind Chimica Spa Derivati dell'acido piroglutammico, loro preparazioni e composizioni farmaceutiche che li contengono
AU2002363939A1 (en) * 2001-11-20 2003-06-10 Seattle Genetics, Inc. Treatment of immunological disorders using anti-cd30 antibodies
EP1688161A1 (en) * 2004-11-02 2006-08-09 Switch Biotech Aktiengesellschaft Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis
TW200711649A (en) * 2005-06-17 2007-04-01 Combinatorx Inc Combination therapy for the treatment of immunoinflammatory disorders

Also Published As

Publication number Publication date
SI2934520T1 (sl) 2017-03-31
US20150352081A1 (en) 2015-12-10
JP2016503042A (ja) 2016-02-01
LT2934520T (lt) 2017-01-10
HUE030408T2 (en) 2017-05-29
MA38156B1 (fr) 2017-03-31
AU2012396941A2 (en) 2015-06-18
AU2012396941A1 (en) 2015-05-28
KR20150095772A (ko) 2015-08-21
CY1118633T1 (el) 2017-07-12
SMT201700071B (it) 2017-03-08
ECSP15025570A (es) 2016-01-29
CN104797254A (zh) 2015-07-22
WO2014094839A1 (en) 2014-06-26
ES2615748T3 (es) 2017-06-08
CA2889388A1 (en) 2014-06-26
IL239292A0 (en) 2015-07-30
DK2934520T3 (en) 2017-01-23
PH12015501211A1 (en) 2015-08-17
CN104797254B (zh) 2017-06-06
HRP20161667T1 (hr) 2017-01-27
EA201591184A1 (ru) 2015-10-30
TN2015000159A1 (en) 2016-10-03
ME02559B (me) 2017-02-20
ZA201502983B (en) 2016-11-30
SG11201503281QA (en) 2015-07-30
BR112015011394A2 (pt) 2017-07-11
EP2934520A1 (en) 2015-10-28
EP2934520B1 (en) 2016-11-16
HK1210938A1 (en) 2016-05-13
MA38156A1 (fr) 2016-08-31
PT2934520T (pt) 2017-02-16
MX2015008129A (es) 2015-09-23
PL2934520T3 (pl) 2017-08-31
RS55424B1 (sr) 2017-04-28
JP6058156B2 (ja) 2017-01-11

Similar Documents

Publication Publication Date Title
CL2018000150A1 (es) Compuestos útiles como inmunomoduladores (divisional de solicitud 201600508)
GT201500051A (es) Inhibidores de glucosilceramida sintasa
DOP2014000170A (es) Compuestos de imidazopirrolidinona
CR20140108A (es) Compuesto de ciclopropanoamina
PH12015500850A1 (en) Stable preservative-free mydriatic and anti-inflammatory solutions for injection
EP2827869A4 (en) COMPOSITIONS AND METHODS FOR IMPROVING THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ITS ANALOGUES INCLUDING MESOINDIGO
GT201300215A (es) Inhibidores de glucosilceramida sintasa
UY35353A (es) Un inhibidor de mdm2 derivado de ácido benzoico para el tratamiento del cáncer
EA201591616A1 (ru) Трифторметил-замещенные аннелированные пиримидины и их применение
EA201300669A1 (ru) Замещенные 1-бензилциклоалкилкарбоновые кислоты и их применение
EA201491817A1 (ru) Терапевтическое применение продуктов из косточек винограда шардоне
CL2015001085A1 (es) Formulacion de liberación prolongada que comprende oprozomib y ademas uno o mas polimeros farmaceuticamente aceptables; metodo de preparacion de la formulacion; metodo para tratar cancer.
MX2015013091A (es) Metodos mejorados de uso para secretoglobinas humanas recombinantes.
CO6731081A2 (es) Método para producir y usar un copolímero de carboximetilcelulosa sódica y gosipol
MX2016006544A (es) Witanolidos utiles para el tratamiento de enfermedades neurodegenerativas.
UY35197A (es) Formulaciones topicas que contienen pidotimod
MX2015016490A (es) Esteres sulfatados de acidos oligohidroxicarboxilicos, y uso de los mismos.
MX2020006075A (es) Composiciones farmaceuticas de bendamustina.
PH12015501210A1 (en) Use of pidotimod to treat psoriasis
MX2015008171A (es) Formulacion que comprende agomelatina amorfa.
EA201301340A1 (ru) Фармацевтическая композиция, обладающая нейропротекторным действием, её применение и способы повышения жизнеспособности и профилактики или лечения цереброваскулярных и нейродегенеративных заболеваний
MY177715A (en) Use of pidotimod to treat atopic dermatitis
PE20151159A1 (es) Uso de pidotimod para tratar la dermatitis atopica
GR1008778B (el) Κρεμα εξωτερικης χρησεως
CU20110091A7 (es) Terapia de combinación con epoxicetonas peptídicas

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20210715